[1] Lawitz E, Flisiak R, Abunimeh M, et al. Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection. Liver Int,2020,40(5):1032-1041.
[2] Karimi-Sari H, Hosseini MA, Nikjoo N, et al. Patient-reported outcomes of sleep, mood and quality of life after treatment of chronic hepatitis C infection using direct-acting antiviral agents. Clin Microbiol Infect,2020,26(8):1093-1093.
[3] AbdEl-Maksoud HA, Elharrif MG, El-Hamid OA, et al. Monitoring of iron, lipid and liver profiles in egyptian hepatitis C virus patients on sofosbuvir therapy. J Infect Public Health,2022,15(3):277-281.
[4] Davidov Y, Kleinbaum Y, Inbar Yet, al. Noninvasive assessment of fibrosis regression after direct-acting antiviral treatment in hepatitis C virus patients. Isr Med Assoc J,2021,23(12):794-800.
[5] Alexander GJ. An association between hepatitis C virus infection and type 2 diabetes mellitus: what is the connection? Ann Intern Med,2000,133(8):650-652.
[6] Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology,2004,126(3):840-848.
[7] Petit JM, Minello A, Texier V, et al. Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: A case-control study: response to petit et al. Diabetes Care,2006,29(9):2180-2180.
[8] Maqbool MA, Imache MR, Higgs MRet, et al. Regulation of hepatitis C virus replication by nuclear translocation of nonstructural 5A protein and transcriptional activation of host genes. J Virol,2013,87(10):5523-5539.
[9] Cheng CH, Chu CY, Chen HL, et al. Virus elimination by direct-acting antiviral agents impacts glucose homeostasis in chronic hepatitis C patients. Front Endocrinol (Lausanne),2022,12:799382.
[10] Sabry A, Elsaeed A, Eletreby S, et al. Effect of direct acting antiviral drugs in hepatitis c virus infected egyptian patients with nephropathy: A single center study. Journal of Hepatology and Gastrointestinal Disorders,2022,8(1):1-7.
[11] Tahata Y, Hikita H, Mochida S, et al. Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis. J Gastroenterol,2022,57(2):120-132.
[12] Mawatari S, Kumagai K, Oda K, et al. Features of patients who developed hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C virus. PloS One,2022,17(1):e0262267-e0262267.
[13] Higuera-de-la-Tijera F, Flores-García NC, Kershenobich D, et al. Hepatocellular carcinoma after direct antiviral agents for hepatitis c in patients with decompensated cirrhosis. Annals of Hepatology,2022,27(S2):100607.
[14] Seko Y, Moriguchi M, Takahashi A, et al. Hepatitis C virus eradication prolongs overall survival in hepatocellular carcinoma patients receiving molecular-targeted agents. J Gastroenterol,2022,57(2):90-98.
[15] Cohen-Bucay A, Francis JM, Gordon CE. Timing of hepatitis C virus infection treatment in kidney transplant candidates. Hemodial Int,2018,22 (S1):61-70.
[16] Varotti G, Dodi F, Paoletti E, et al. Successful antiviral treatment with direct-acting antivirals for hepatitis C virus infection during peritransplant period in a kidney transplant recipient. Case Rep Transplant,2021,Dec 11:1948560.
[17] Arias ABV, Villegas Herrera MT, Arco Sánchez A, et al. Indication for liver transplantation after direct-acting agents in the treatment of patients with hepatitis C. Transplant Proc,2021,54(1):32-34.
[18] De Santis A, Maggi D, Lubrano Lobianco F. Safety and efficacy of directly‐acting antiviral therapy for chronic hepatitis C virus in elderly people. Aging Med (Milton),2021,4(4):304-316.
[19] Kramer JR, Puenpatom A, Cao Y, et al. Treatment of hepatitis C virus infection in people with opioid use disorder: a real-world study of elbasvir/grazoprevir in a US Department of Veterans Affairs population. Am J Drug Alcohol Abuse,2022,Jan 25:1-9.
[20] Syed TA, Cherian R, Lewis S, et al. Telemedicine HCV treatment in department of corrections results in high SVR in era of direct-acting antivirals. J Viral Hepat,2021,28(1):209-212.
[21] Goodman ZD, Makhlouf HR, Liu L, et al. Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial. Hepatology,2008,47(3):836-843.
[22] Schwarz KB, Rosenthal P, Murray KF, et al. Ledipasvir-sofosbuvir for 12 weeks in children 3 to <6 years old with chronic hepatitis C. Hepatology,2020,71(2):422-430.
[23] Murray KF, Balistreri WF, Bansal S, et al. Safety and efficacy of ledipasvir-sofosbuvir with or without ribavirin for chronic hepatitis C in children ages 6-11. Hepatology,2018,68(6):2158-2166.
[24] Pokorska-S＇ piewak M, Dobrzeniecka A, Marczyńska M. One-Year outcomes after ledipasvir/sofosbuvir treatment of chronic hepatitis C in teenagers with and without significant liver fibrosis—a case series report. Viruses,2021,13(8):1518-1518.
[25] El-Sayed MH, Ebeid FSE, Zekri AR, et al. Ledipasvir-sofosbuvir in adolescents with chronic hepatitis C and hematological malignancies undergoing chemotherapy. J Pediatr Gastroenterol Nutr,2022,74(5):626-630.
[26] Altinbas S, Holmes JA, Altinbas A. Hepatitis C virus infection in pregnancy: An update. Gastroenterol Nurs,2020,43(1):12-21.
[27] Kurokawa K, Ohki T, Kato J, et al. Hepatitis C virus relapse after successful treatment with direct-acting antivirals, followed by sarcomatous changes in hepatocellular carcinoma: a case report. J Med Case Rep,2020,14(1):62-62.
[28] Qatomah A, Bukhari M, Cupler E, et al. Acute reversible rhabdomyolysis during direct-acting antiviral hepatitis C virus treatment: a case report. J Med Case Rep,2021,15(1):627-627.
[29] Zhou Y, Xie W, Zheng CJ, et al. Hypoglycemia associated with direct acting anti-hepatitis C virus drugs: an epidemiologic surveillance study of the FDA adverse event reporting system (FAERS). Clin Endocrinol (Oxf),2021,96(5):690-697. |
